Nascent Biotech, Inc. (NBIO)
USD 0.01
(44.44%)
USD 0.01
(44.44%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 808.79 Thousand USD | -47.86% |
| 2023 | 1.55 Million USD | 99.66% |
| 2022 | 776.89 Thousand USD | -36.53% |
| 2021 | 1.22 Million USD | -57.49% |
| 2020 | 2.87 Million USD | 369.16% |
| 2019 | 613.63 Thousand USD | 201.73% |
| 2018 | 203.37 Thousand USD | 22.51% |
| 2017 | 165.99 Thousand USD | -94.41% |
| 2016 | 2.97 Million USD | -5.55% |
| 2015 | 3.14 Million USD | 100.91% |
| 2014 | 1.56 Million USD | -19.81% |
| 2013 | 1.95 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 808.79 Thousand USD | 32.39% |
| 2024 Q1 | 1.23 Million USD | -20.45% |
| 2024 FY | 808.79 Thousand USD | -47.86% |
| 2024 Q3 | 610.93 Thousand USD | -41.76% |
| 2024 Q2 | 1.04 Million USD | -14.98% |
| 2023 Q2 | 2.38 Million USD | 47.45% |
| 2023 FY | 1.55 Million USD | 99.66% |
| 2023 Q4 | 1.55 Million USD | -19.63% |
| 2023 Q3 | 1.92 Million USD | -19.21% |
| 2023 Q1 | 1.62 Million USD | 108.54% |
| 2022 Q2 | 1.15 Million USD | 3.66% |
| 2022 Q3 | 1.19 Million USD | 4.26% |
| 2022 FY | 776.89 Thousand USD | -36.53% |
| 2022 Q4 | 776.89 Thousand USD | -35.24% |
| 2022 Q1 | 1.11 Million USD | -9.3% |
| 2021 Q3 | 1.3 Million USD | 43.36% |
| 2021 Q2 | 910.21 Thousand USD | -34.89% |
| 2021 Q1 | 1.39 Million USD | -51.44% |
| 2021 FY | 1.22 Million USD | -57.49% |
| 2021 Q4 | 1.22 Million USD | -6.2% |
| 2020 Q2 | 806.61 Thousand USD | 28.87% |
| 2020 FY | 2.87 Million USD | 369.16% |
| 2020 Q1 | 625.93 Thousand USD | 2.0% |
| 2020 Q4 | 2.87 Million USD | 201.67% |
| 2020 Q3 | 954.32 Thousand USD | 18.31% |
| 2019 Q3 | 594.55 Thousand USD | 18.72% |
| 2019 Q1 | 10.77 Million USD | 5195.79% |
| 2019 FY | 613.63 Thousand USD | 201.73% |
| 2019 Q2 | 500.8 Thousand USD | -95.35% |
| 2019 Q4 | 613.63 Thousand USD | 3.21% |
| 2018 Q3 | 157.09 Thousand USD | 25.13% |
| 2018 FY | 203.37 Thousand USD | 22.51% |
| 2018 Q2 | 125.54 Thousand USD | -43.12% |
| 2018 Q1 | 220.7 Thousand USD | 32.95% |
| 2018 Q4 | 203.37 Thousand USD | 29.46% |
| 2017 Q1 | 1.66 Million USD | -43.83% |
| 2017 Q4 | 165.99 Thousand USD | -14.4% |
| 2017 FY | 165.99 Thousand USD | -94.41% |
| 2017 Q3 | 193.91 Thousand USD | 39.56% |
| 2017 Q2 | 138.94 Thousand USD | -91.67% |
| 2016 Q2 | 1.57 Million USD | -53.48% |
| 2016 Q1 | 3.38 Million USD | 7.75% |
| 2016 FY | 2.97 Million USD | -5.55% |
| 2016 Q4 | 2.97 Million USD | 76.1% |
| 2016 Q3 | 1.68 Million USD | 7.0% |
| 2015 FY | 3.14 Million USD | 100.91% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q4 | 3.14 Million USD | 61.59% |
| 2015 Q2 | 1.68 Million USD | 0.0% |
| 2015 Q3 | 1.94 Million USD | 15.52% |
| 2014 Q4 | 1.56 Million USD | 0.0% |
| 2014 FY | 1.56 Million USD | -19.81% |
| 2013 FY | 1.95 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -2848.252% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 91.456% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 98.884% |
| Rebus Holdings, Inc. | 5.24 Million USD | 84.571% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 98.629% |
| Qrons Inc. | 1.48 Million USD | 45.672% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | 34.041% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 98.92% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -1709.544% |
| Skye Bioscience, Inc. | 14.07 Million USD | 94.253% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 98.483% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 91.559% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -91.854% |
| SQZ Biotechnologies Company | 50.03 Million USD | 98.384% |
| Intellipharmaceutics International Inc. | 12 Million USD | 93.265% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 79.0% |
| Mesoblast Limited | 188.44 Million USD | 99.571% |
| Marizyme, Inc. | 26.67 Million USD | 96.968% |
| Genus plc | 485 Million USD | 99.833% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 86.157% |
| Pharming Group N.V. | 244.07 Million USD | 99.669% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 59.764% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 67.858% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 78.716% |
| ContraFect Corporation | 32.53 Million USD | 97.514% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 59.179% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 78.87% |
| IMV Inc. | 37.93 Million USD | 97.868% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 93.133% |
| MultiCell Technologies, Inc. | 1617.67 USD | -49897.465% |
| ONE Bio Corp. | 27.49 Million USD | 97.058% |
| Accustem Sciences Inc. | 1.07 Million USD | 25.059% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 98.955% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 61.76% |
| Q BioMed Inc. | 8.13 Million USD | 90.055% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.025% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 84.283% |
| Biomind Labs Inc. | 1.49 Million USD | 46.03% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.319% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 91.055% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 95.605% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 43.593% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -469.192% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -302.153% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 85.924% |
| GB Sciences, Inc. | 5.41 Million USD | 85.071% |
| Alpha Cognition Inc. | 7.16 Million USD | 88.712% |
| HST Global, Inc. | 593.59 Thousand USD | -36.254% |
| CSL Limited | 18.62 Billion USD | 99.996% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 35.769% |
| Halberd Corporation | 728.71 Thousand USD | -10.988% |
| Enzolytics Inc. | 365.26 Million USD | 99.779% |
| Agentix Corp. | 2.51 Million USD | 67.784% |
| Resverlogix Corp. | 67.39 Million USD | 98.8% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 3.569% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.818% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 52.812% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 96.732% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 93.205% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 77.933% |
| AVAX Technologies, Inc. | 3.99 Million USD | 79.748% |
| Zenith Capital Corp. | 27.56 Thousand USD | -2833.708% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.939% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -238.898% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 78.342% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -18.795% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 70.173% |
| Kadimastem Ltd | 3.5 Million USD | 76.924% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -1108.436% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 98.391% |
| BioStem Technologies, Inc. | 15.9 Million USD | 94.915% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -74.047% |
| LadRx Corporation | 2.2 Million USD | 63.245% |
| Cell Source, Inc. | 15.8 Million USD | 94.883% |
| Regen BioPharma, Inc. | 5.45 Million USD | 85.18% |
| Regen BioPharma, Inc. | 5.45 Million USD | 85.18% |
| NovAccess Global Inc. | 7.86 Million USD | 89.711% |
| Affymax, Inc. | 8.87 Million USD | 90.883% |
| Itoco Inc. | 1.65 Million USD | 51.076% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 60.577% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 86.629% |
| Mobile Lads Corp. | 1.31 Million USD | 38.424% |
| CytoDyn Inc. | 127.89 Million USD | 99.368% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -1834.96% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 48.365% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 92.677% |
| SYBLEU INC | 681.41 Thousand USD | -18.694% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 86.745% |
| International Stem Cell Corporation | 5.27 Million USD | 84.673% |
| Bioxytran, Inc. | 3.24 Million USD | 75.11% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -29.24% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 82.483% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 98.027% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 96.367% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 60.067% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 85.236% |
| Neutra Corp. | 973.52 Thousand USD | 16.921% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 97.212% |
| PureTech Health plc | 125.58 Million USD | 99.356% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 78.473% |
| IXICO plc | 1.9 Million USD | 57.438% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 96.06% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.217% |
| CSL Limited | 18.62 Billion USD | 99.996% |
| Cellectis S.A. | 249.36 Million USD | 99.676% |